Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Faculty Members have conducted research related to the Prostate-Specific Antigen Density and Gleason Score Predict Adverse Pathologic Features in Patients With Clinically Localized Prostate Cancer
Mohammad Reza Nowroozi
Mohammad Reza Nowroozi

Professor of Urology

Department Urology

School of Medicine

Imam Khomeini Hospital Complex

Uro-Oncology Research Center

Tehran University of Medical Sciences

All Documents
1. Antimicrobial Resistance Profiles for Bacteria Isolated From Rectal Swabs in Patients Candidate for Prostate Biopsy, Journal of Clinical Urology (2024)
2. Impaired Monocyte-Derived Dendritic Cell Phenotype in Prostate Cancer Patients: A Phenotypic Comparison With Healthy Donors, Cancer Reports (2024)
3. Shell-Sheddable and Charge Switchable Magnetic Nanoparticle As Ph-Sensitive Nanocarrier for Targeted Drug Delivery Applications, Polymers for Advanced Technologies (2024)
4. A Case Report of a Self-Inserted Foreign Body in the Urethra/Bladder Causing Urinary Calculus Formation, and a Review of the Literature, Heliyon (2023)
5. A Case Report of a Self-Inserted Foreign Body in the Urethra/Bladder Causing Urinary Calculus Formation, and a Review of the Literature, Heliyon (2023)
6. Assessment of Tolerability, Response and Complications of Concurrent Chemoradiation With Capecitabine and Cisplatin in Muscle-Invasive Bladder Cancer; a Single Arm Study, Clinical Genitourinary Cancer (2023)
7. Cardiovascular Surgical Experiences of Ivc Tumor and Thrombus: Operative Strategies Based on 51 Consecutive Patients, Asian Cardiovascular and Thoracic Annals (2023)
8. Cardiovascular Surgical Experiences of Ivc Tumor and Thrombus: Operative Strategies Based on 51 Consecutive Patients, Asian Cardiovascular and Thoracic Annals (2023)
9. Evaluation of Igf2, Krt14, and Krt20 As Urinary Biomarkers in Patients With Bladder Cancer, Reports of Biochemistry and Molecular Biology (2023)
10. Log Odds of Positive Lymph Nodes (Lodds) As an Independent Predictor of Overall Survival Following Radical Cystectomy in Urothelial Bladder Cancer: Time to Rethink Conventional Node Staging, Clinical Genitourinary Cancer (2023)
11. Trends in Incidence of Prostate Cancer in Iran and Its 31 Provinces During 2003 - 2016, International Journal of Cancer Management (2023)
12. Association Between Preoperative De Ritis (Ast/Alt) Ratio and Oncological Outcomes Following Radical Cystectomy in Patients With Urothelial Bladder Cancer, Clinical Genitourinary Cancer (2022)
13. Biofilm Formation, Antimicrobial Resistance and Biofilm-Related Genes Among Uropathogens Isolated From Catheterized Uro-Oncology Patients, Journal of Advances in Medical and Biomedical Research (2022)
14. Diagnostic and Therapeutic Implications of Sortilin Expressed on the Surface of Bladder Carcinoma Cells, Iranian Journal of Pathology (2022)
15. Effect of Treatment Modality on Quality of Life Among Patients With Urinary Bladder Cancer, International Journal of Urological Nursing (2022)
16. Fruhis Significantly Increases the Anti-Benign Prostatic Hyperplasia Effect of Lycopene: A Double-Blinded Randomized Controlled Clinical Trial, Frontiers in Nutrition (2022)
17. Genetic and Epigenetic Evaluation of Human Spermatogonial Stem Cells Isolated by Macs in Different Two and Three-Dimensional Culture Systems, Cell Journal (2022)
18. Molecular Characteristics of Bladder Tumor: Increased Gene Expression of Mage-A6 and Mage-A11 With Decreased Microrna-34A and Microrna-125B, Iranian Journal of Allergy# Asthma and Immunology (2022)
19. Opium Use and Risk of Bladder Cancer: A Multi-Centre Case-Referent Study in Iran, International Journal of Epidemiology (2022)
20. Prostaglandin Synthase 2/Cyclooxygenase 2 Gene Polymorphisms and Susceptibility to Urothelial Bladder Cancer in an Iranian Population, Middle East Journal of Cancer (2022)
21. The Association of Cell Surface Fibromodulin Expression and Bladder Carcinoma, Urology Journal (2022)
22. The Effect of Melatonin on Improving the Benign Prostatic Hyperplasia Urinary Symptoms, a Randomized Clinical Trial, Urology Journal (2022)
23. The Effect of Melatonin on Improving the Benign Prostatic Hyperplasia Urinary Symptoms, a Randomized Clinical Trial, Urology Journal (2022)
24. The Prospect of Targeting T Cell Immunoglobulin and Mucin-Domain Containing-3 in Renal Cell Carcinoma Immunotherapy, Scandinavian Journal of Immunology (2022)
25. A Possible Protective Role for Bacillus Calmette-Guerin Therapy in Urinary Bladder Cancer in the Era of Covid-19: A Brief Report, Clinical and Experimental Vaccine Research (2021)
26. Effects of Admission Age and Gleason Score on the State Transition in Elderly Patients With Prostate Cancer Using a Multi-State Model, Iranian Journal of Ageing (2021)
27. Global, Regional and National Burden of Bladder Cancer and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019, BMJ Global Health (2021)
28. Infection With Human Papillomavirus As a Potential Risk Factor for Prostate Cancer: A Case-Control Study, Archives of Clinical Infectious Diseases (2021)
29. Primary Squamous Cell Carcinoma of Renal Parenchyma: Case Report and Review of Literature, Urology Case Reports (2021)
30. Renal Ewing's Sarcoma With the Spread of Tumor Thrombosis to the Inferior Vena Cava: Case Report, Tehran University Medical Journal (2021)
31. Seroprevalence of Herpes Simplex Virus Type 2 and Human Herpesvirus Type 8 Among Prostate Cancer Patients Compared to Cancer-Free Men, International Journal of Cancer Management (2021)
32. The Epigenetic Assessment of Human Spermatogenic Cells Derived From Obstructive Azoospermic Patients in Different Culture Systems, Urology Journal (2021)
33. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)
34. The Role of Nutritional Interventions in Prostate Cancer: A Review, Journal of Research in Medical Sciences (2021)
35. Association of Human Papilloma Virus (Hpv) Infection With Oncological Outcomes in Urothelial Bladder Cancer, Infectious Agents and Cancer (2020)
36. Financial Burden of Prostate Cancer Screening: Changing Trends After Health Sector Reform in a Developing Country, Urology Journal (2020)
37. Investigation of the Relationship Between Prostate Specific Antigen Doubling Time and the Severity of a Malignant Tumor of the Prostate, Tehran University Medical Journal (2020)
38. Molecular Epidemiology of Carbapenemase-Producing Pseudomonas Aeruginosa Isolated From an Iranian University Hospital: Evidence for Spread of High-Risk Clones, Infection and Drug Resistance (2020)
39. Monoclonal Antibody Against Ror1 Induces Apoptosis in Human Bladder Carcinoma Cells, Avicenna Journal of Medical Biotechnology (2020)
40. Role of Chronic Inflammation As a Predictor of Upstaging/Upgrading in Prostate Cancer: Finding a New Group Eligible for Active Surveillance, Urology Journal (2020)
41. Serum and Urine Levels of Vascular Endothelial Growth Factor As Prognostic Markers in Patients With Bladder Cancer, Middle East Journal of Cancer (2020)
42. A Review on the Role of M2 Macrophages in Bladder Cancer; Pathophysiology and Targeting, International Immunopharmacology (2019)
43. Cancer-Testis Antigens As New Candidate Diagnostic Biomarkers for Transitional Cell Carcinoma of Bladder, Pathology and Oncology Research (2019)
44. Differentiation of Spermatogonial Stem Cells by Soft Agar Three-Dimensional Culture System, Artificial Cells# Nanomedicine and Biotechnology (2019)
45. Erratum: Global, Regional, and National Comparative Risk Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks for 195 Countries and Territories, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017 (The Lancet (2018) 392(10159) (1923–1994), (S0140673618322256), (10.1016/S0140-6736(18)32225-6)), The Lancet (2019)
46. Erratum: Global, Regional, and National Comparative Risk Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks for 195 Countries and Territories, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017 (The Lancet (2018) 392(10159) (1923–1994), (S0140673618322256), (10.1016/S0140-6736(18)32225-6)), The Lancet (2019)
47. Global, Regional and National Burden of Bladder Cancer, 1990 to 2016: Results From the Gbd Study 2016, Journal of Urology (2019)
48. Global, Regional and National Burden of Testicular Cancer, 1990–2016: Results From the Global Burden of Disease Study 2016, BJU International (2019)
49. Radical Cystectomy for Management of Inflammatory Myofibroblastic Tumor of the Urinary Bladder: A Rare Case Report, Urology Case Reports (2019)
50. Second Transurethral Resection of Bladder Tumor: Is It Necessary in All T1 And/Or High-Grade Tumors?, Urology Journal (2019)
51. Simultaneous Cesarean Section and Radical Nephrectomy With Tumor Thrombectomy During Pregnancy, Acta Medica Iranica (2019)
52. Toll-Like Receptors: The Role in Bladder Cancer Development, Progression and Immunotherapy, Scandinavian Journal of Immunology (2019)
53. Erratum: Global, Regional, and National Age-Sex-Specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980–2017: A Systematic Analysis for the Global Burden of Disease Study 2017 (The Lancet (2018) 392(10159) (1736–1788)(S0140673618322037)(10.1016/S0140-6736(18)32203-7)), The Lancet (2018)
54. Erratum: Global, Regional, and National Age-Sex-Specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980–2017: A Systematic Analysis for the Global Burden of Disease Study 2017 (The Lancet (2018) 392(10159) (1736–1788)(S0140673618322037)(10.1016/S0140-6736(18)32203-7)), The Lancet (2018)
55. Feasibility and Safety of Ultrasonography Guidance and Flank Position During Percutaneous Nephrolithotomy, Journal of Urology (2018)
56. Global, Regional, and National Age-Sex-Specific Mortality and Life Expectancy, 1950-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
57. Global, Regional, and National Age-Sex-Specific Mortality and Life Expectancy, 1950-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
58. Global, Regional, and National Age-Sex-Specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980–2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
59. Global, Regional, and National Age-Sex-Specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980–2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
60. Global, Regional, and National Comparative Risk Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
61. Global, Regional, and National Comparative Risk Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
62. Global, Regional, and National Disability-Adjusted Life-Years (Dalys) for 359 Diseases and Injuries and Healthy Life Expectancy (Hale) for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
63. Global, Regional, and National Disability-Adjusted Life-Years (Dalys) for 359 Diseases and Injuries and Healthy Life Expectancy (Hale) for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
64. Global, Regional, and National Incidence, Prevalence, and Years Lived With Disability for 354 Diseases and Injuries for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
65. Global, Regional, and National Incidence, Prevalence, and Years Lived With Disability for 354 Diseases and Injuries for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
66. Measuring Progress From 1990 to 2017 and Projecting Attainment to 2030 of the Health-Related Sustainable Development Goals for 195 Countries and Territories: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
67. Measuring Progress From 1990 to 2017 and Projecting Attainment to 2030 of the Health-Related Sustainable Development Goals for 195 Countries and Territories: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
68. Odf4, Magea3, and Mageb4: Potential Biomarkers in Patients With Transitional Cell Carcinoma, Iranian Biomedical Journal (2018)
69. Population and Fertility by Age and Sex for 195 Countries and Territories, 1950–2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
70. Population and Fertility by Age and Sex for 195 Countries and Territories, 1950–2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
71. Management of Hepatic Granulomatous Tuberculosis After Bcg Therapy for Bladder Cancer, Urology Case Reports (2017)
72. Morphological and Ultrastructural Studies of Human Spermatogonial Stem Cells From Patients With Maturation Arrest, Andrologia (2017)
73. Reference Gene Validation for Relative Quantification Analysis of Transcripts in Urinary Exfoliated Cells Among Urothelial Bladder Carcinoma Patients, Meta Gene (2017)
74. Development, Validation and Comparison of Two Nomograms Predicting Prostate Cancer at Initial 12-Core Biopsy, Asia-Pacific Journal of Clinical Oncology (2016)
75. Her2 Gene Amplification in Patients With Prostate Cancer: Evaluating a Cish-Based Method, Oncology Letters (2016)
76. Is There a Role for Genetic Information in Risk Assessment and Decision Making in Prostate Cancer?, Nephro-Urology Monthly (2016)
77. Prostate-Specific Antigen Density and Gleason Score Predict Adverse Pathologic Features in Patients With Clinically Localized Prostate Cancer, Nephro-Urology Monthly (2016)
78. Relationship Between Perineural Invasion in Prostate Needle Biopsy Specimens and Pathologic Staging After Radical Prostatectomy, Nephro-Urology Monthly (2016)
79. Applying Extender Devices in Patients With Penile Dysmorphophobia: Assessment of Tolerability, Efficacy, and Impact on Erectile Function, Journal of Sexual Medicine (2015)
80. Assessment of Testicular Perfusion Prior to Sperm Extraction Predicts Success Rate and Decreases the Number of Required Biopsies in Patients With Non-Obstructive Azoospermia, International Urology and Nephrology (2015)
81. Comparison of the Efficacy of Two Brands of Triptorelin (Microrelin and Diphereline) in Reducing Prostate-Specific Antigen and Serum Testosterone in Prostate Cancer: A Double-Blinded Randomized Clinical Trial, Nephro-Urology Monthly (2015)
82. Concurrent Down-Regulation of Pten and Nkx3.1 Expression in Iranian Patients With Prostate Cancer, International Braz J Urol (2015)
83. Molecular Characterization of Kras, Braf, and Egfr Genes in Cases With Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations, Clinical Laboratory (2015)
84. Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Testicular Cancer: A Single Center Experiences, Nephro-Urology Monthly (2015)
85. Transition Zone Prostate Specific Antigen Density Improves Prostate Cancer Detection in Iranian Men, Nephro-Urology Monthly (2015)
86. Transition Zone Prostate-Specific Antigen Density Could Better Guide the Rebiopsy Strategy in Men With Prostate Inflammation at Initial Biopsy, Urology (2015)
87. Unusual Presentation of Renal Cell Carcinoma in Crossed Ectopic Kidney, Nephro-Urology Monthly (2015)
88. Xenotransplantation Assessment: Morphometric Study of Human Spermatogonial Stem Cells in Recipient Mouse Testes, Andrologia (2015)